(E)-3-(4-bromophenyl)-N,N-dimethylprop-2-en-1-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-3-(4-bromophenyl)-N,N-dimethylprop-2-en-1-amine
• 英文别名: p-Bromo-N,N-dimethylcinnamylamine；[(E)-3-(4-Bromo-phenyl)-allyl]-dimethyl-amine
• 化学式: C₁₁H₁₄BrN
• 分子量: 240.143
• InChiKey: OMEFPROJHCNPAS-ONEGZZNKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-3-(4-bromophenyl)-N,N-dimethylprop-2-en-1-amine 在 三(三苯基膦)羰基氢化铑 、 decamethylrhenocene 二硫化碳 、 sodium hydroxide 、 氢气 、 羟胺 、 四丁基硫酸氢铵 作用下， 以 二氯甲烷 、 甲苯 、 苯 为溶剂， 25.0~140.0 ℃ 、10.13 MPa 条件下， 反应 60.5h， 生成 溴苯那敏
  参考文献：
  名称：

  New Synthetic Route to Pheniramines via Hydroformylation of Functionalyzed Olefins

  摘要：

  DOI：

  10.1021/jo00102a044
• 作为产物：
  描述：

  3-(4-溴苯基)丙-2-烯-1-醇 在 三溴化磷 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 0.17h， 生成 (E)-3-(4-bromophenyl)-N,N-dimethylprop-2-en-1-amine
  参考文献：
  名称：

  An Isothiourea-Catalyzed Asymmetric [2,3]-Rearrangement of Allylic Ammonium Ylides

  摘要：

  Benzotetramisole promotes the catalytic asymmetric [2,,3]-rearrangement of allylic quaternary ammonium salts (either isolated or prepared in situ from p-nitrophenyl bromoacetate and the corresponding allylic amine), generating syn-alpha-amino acid derivatives with excellent diastereo- and enantioselectivity (up to >95:5 dr; up to >99% ee).

  DOI：

  10.1021/ja500758n

文献信息

• Chiral α-Amino Acid/Palladium-Catalyzed Asymmetric Allylation of α-Branched β-Ketoesters with Allylic Amines: Highly Enantioselective Construction of All-Carbon Quaternary Stereocenters
  作者：Ya-Nan Xu、Meng-Zeng Zhu、Shi-Kai Tian

  DOI：10.1021/acs.joc.9b02282

  日期：2019.11.15

  use of allylic amines as allylating agents in the chiral α-amino acid/palladium-catalyzed asymmetric allylation of α-branched β-ketoesters, providing highly enantioselective access to all-carbon quaternary stereocenters. Notably, the formation of a primary amine, a secondary amine, or ammonia as a byproduct has little influence on the enantioselectivity for the catalytic asymmetric synthesis of structurally

  已经开发出一种新的协议，用于将烯丙基胺用作α-支链β-酮酸酯的手性α-氨基酸/钯催化的不对称烯丙基化中的烯丙基化剂，从而提供了对映全碳全季铵立体中心的高度对映选择性。值得注意的是，作为副产物的伯胺，仲胺或氨的形成对结构多样的α，α-二取代的β-酮酯的催化不对称合成的对映选择性几乎没有影响。
• Synthesis, Pharmacological and Biophysical Characterization, and Membrane-Interaction QSAR Analysis of Cationic Amphiphilic Model Compounds
  作者：Christian D. P. Klein、Martin Klingmüller、Christiane Schellinski、Silke Landmann、Stefanie Hauschild、Dieter Heber、Klaus Mohr、A. J. Hopfinger

  DOI：10.1021/jm980694a

  日期：1999.9.1

  of the compounds was determined in Langendorff preparations of guinea pig hearts to assess the membrane-stabilizing action. Quantitative structure-activity relationship (QSAR) models for these endpoints were developed using both intra- and intermolecular QSAR descriptors. Intermolecular membrane-interaction descriptors were derived from molecular dynamics simulations of the compounds in a model phospholipid

  阳离子两亲药物具有与生物中间相相互作用的倾向。这项研究的目的是更深入地了解控制这种相互作用的卡两性药物的分子特性。合成了一系列苯丙胺模型化合物，其中在分子的芳族部分引入了修饰。从磷脂酰丝氨酸单层的（45）Ca（2+）替换用于监测药物与磷脂的结合。测量对二棕榈酰磷脂酸脂质体的相变温度的影响，以评估药物对磷脂组装体的结构组织的干扰作用。在豚鼠心脏的Langendorff制剂中测定化合物的抗心律不齐活性以评估膜稳定作用。使用分子内和分子间QSAR描述符开发了这些终点的定量构效关系（QSAR）模型。分子间膜相互作用描述符是从模型磷脂单层化合物的分子动力学模拟中得出的。使用偏最小二乘回归（PLS）和遗传算法工具，即遗传函数近似（GFA），为所有端点导出了QSAR模型。膜相互作用描述符在解释化合物对DPPA脂质体的相变温度的影响方面似乎特别重要，而其他端点可以通过分子内描述符进行适当建模。磷脂酰丝氨酸
• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-A]PYRIDINE ET [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009047514A1

  公开（公告）日：2009-04-16

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，这些化合物等等，可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，无论是体外还是体内，来抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病况，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病况等，包括增生性疾病如癌症等。
• [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
  申请人：Cancer Research Technology Limited

  公开号：US20140155594A1

  公开（公告）日：2014-06-05

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明涉及治疗化合物领域，更具体地涉及某些三唑化合物（在此称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，其中包括抑制AXL受体酪氨酸激酶功能的化合物。本发明还涉及包括这些化合物的制药组合物，以及使用这些化合物和组合物在体内外抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病症，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病症，包括增生性疾病如癌症等。
• [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds and their use
  申请人：Pavé Grégoire Alexandre

  公开号：US08431596B2

  公开（公告）日：2013-04-30

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称TAZ化合物），尤其是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，它们可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包含这种化合物的制药组合物，并且在体内外使用这种化合物和组合物来抑制AXL受体酪氨酸激酶功能，治疗由AXL受体酪氨酸激酶介导的疾病和病状，通过抑制AXL受体酪氨酸激酶功能改善这些疾病和病状，包括增生性疾病如癌症等。